Plasmakoncentrationer af bosentanmetaboliter steg til omkring det dobbelte hos disse patienter i sammenligning med personer med normal nyrefunktion.
Plasma concentrations of bosentan metabolites increased about 2-fold in these patients as compared to subjects with normal renal function.